Literature DB >> 26488421

Structural modeling of HLA-B*1502/peptide/carbamazepine/T-cell receptor complex architecture: implication for the molecular mechanism of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.

Peng Zhou1, Shilei Zhang1, Yewang Wang1, Chao Yang1, Jian Huang1.   

Abstract

Drug-induced adverse reactions are a significant problem in healthcare worldwide and are estimated to cost billions of dollars annually in the United States. A portion of such reactions is observed to strongly associate with certain human leukocyte antigen (HLA) alleles; one of the strongest associations is the HLA-B*1502 protein with carbamazepine (CBZ)-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) - the odds ratio value can even be higher than one thousand. The particularly strong association in CBZ-induced SJS/TEN suggests that the HLA-B*1502 is not only a genetic marker but also a participant in the pathogenesis of the disease. In the current study, we attempt to computationally model the atomic-level structure of the complete HLA-B*1502/peptide/CBZ/T-cell receptor (TCR) complex architecture based on prior knowledge obtained from epidemiological investigations as well as in vitro and in vivo assays. The model tells a different story about the molecular mechanism of CBZ-induced SJS/TEN from that previously reported for abacavir (ABC)-induced hypersensitivity (HSR); the CBZ molecule is located at the interface between HLA-B*1502/peptide and TCR, directly contacts the P3-P6 residues of antigen peptide, and bound within a pocket region encompassed by two TCR CDR3 fingers. Molecular dynamics simulation and binding energy analysis further reveal that the CBZ shows considerably high affinity to TCR over HLA-B*1502/peptide, which can tightly interact with the former rather than the latter. From the model, two hypotheses are proposed that can well explain most previous observations and are expected to guide next wet-lab experiments. This study could help to promote our understanding of the molecular mechanism and pathological implication underlying CBZ-induced SJS/TEN.

Entities:  

Keywords:  CBZ-induced SJS/TEN; HLA-B*1502; HLA–drug association; T-cell receptor; adverse drug reaction; peptide

Mesh:

Substances:

Year:  2015        PMID: 26488421     DOI: 10.1080/07391102.2015.1092476

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  23 in total

1.  Electrostatic mechanism of V600E mutation-induced B-Raf constitutive activation in colorectal cancer: molecular implications for the selectivity difference between type-I and type-II inhibitors.

Authors:  Tie Liu; Zhaoshun Wang; Peng Guo; Na Ding
Journal:  Eur Biophys J       Date:  2018-09-14       Impact factor: 1.733

Review 2.  Multiple Drug Hypersensitivity.

Authors:  Werner J Pichler; Yuttana Srinoulprasert; James Yun; Oliver Hausmann
Journal:  Int Arch Allergy Immunol       Date:  2017-03-18       Impact factor: 2.749

3.  Rational creation and systematic analysis of cervical cancer kinase-inhibitor binding profile.

Authors:  Min Han; Dongdong Sun
Journal:  J Comput Aided Mol Des       Date:  2019-06-15       Impact factor: 3.686

4.  Computational redesign of human respiratory syncytial virus epitope as therapeutic peptide vaccines against pediatric pneumonia.

Authors:  Xiangxiang Shi; Jun Zheng; Tingting Yan
Journal:  J Mol Model       Date:  2018-03-02       Impact factor: 1.810

5.  Grafting, Stripping and Stapling of Helical Peptides from the Dimerization Interface of ONFH-Related Bone Morphogenetic Protein-2.

Authors:  Wenqi Song; Kunzheng Wang; Wei Wang; Pei Yang; Xiaoqian Dang
Journal:  Protein J       Date:  2019-02       Impact factor: 2.371

6.  Structural Identification and Systematic Comparison of Phorbol Ester, Dioleoylglycerol, Alcohol and Sevoflurane Binding Sites in PKCδ C1A Domain.

Authors:  Lijie Shi
Journal:  Protein J       Date:  2018-12       Impact factor: 2.371

7.  Rational design of type-IA receptor-derived cyclic peptides to target human bone morphogenic protein 2.

Authors:  Xiaohua Fan; Hai Xia; Xiaoyun Liu; Benying Li; Jun Fang
Journal:  J Biosci       Date:  2019-12       Impact factor: 1.826

Review 8.  HLAs: Key regulators of T-cell-mediated drug hypersensitivity.

Authors:  A J Redwood; R K Pavlos; K D White; E J Phillips
Journal:  HLA       Date:  2018-01       Impact factor: 4.513

Review 9.  The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions.

Authors:  Patricia T Illing; Anthony W Purcell; James McCluskey
Journal:  Immunogenetics       Date:  2017-07-10       Impact factor: 3.330

10.  Electrostatic explanation of D1228V/H/N-induced c-Met resistance and sensitivity to type I and type II kinase inhibitors in targeted gastric cancer therapy.

Authors:  Zhen Xu; Pingping Hu; Dong Fang; Lingna Ni; Jianzhong Xu
Journal:  J Mol Model       Date:  2019-01-03       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.